Illumina Inc. (ILMN): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Illumina ( ILMN) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.4%. By the end of trading, Illumina fell $1.80 (-1.1%) to $166.55 on average volume. Throughout the day, 2,497,072 shares of Illumina exchanged hands as compared to its average daily volume of 1,930,500 shares. The stock ranged in price between $163.09-$168.54 after having opened the day at $167.68 as compared to the previous trading day's close of $168.35. Other companies within the Health Care sector that declined today were: Biostar Pharmaceuticals ( BSPM), down 19.2%, Reliv' International ( RELV), down 11.6%, Baxano Surgical ( BAXS), down 10.7% and ZELTIQ Aesthetics ( ZLTQ), down 9.3%.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $22.0 billion and is part of the drugs industry. Shares are up 55.0% year to date as of the close of trading on Friday. Currently there are 7 analysts that rate Illumina a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the positive front, Northwest Biotherapeutics ( NWBO), up 29.6%, Egalet ( EGLT), up 25.6%, Arrhythmia Research Technology ( HRT), up 19.4% and Rosetta Genomics ( ROSG), up 16.4% , were all gainers within the health care sector with Teva Pharmaceutical Industries ( TEVA) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Trader's Daily Notebook: Anemic Trading Would Be an Improvement